Compare Elevance Health Inc. Common Stock (ELV) vs QXO Inc. Common Stock (QXO) Price & Performance

Elevance Health (ELV) trades at $425.27, up 0.75% with a bullish technical outlook and strong institutional support. The stock shows consistent earnings beats with Q1 2026 EPS of $12.58 beating expectations by 16%, while maintaining solid fundamentals with $199.13B revenue and 11.2% ROE. Recent Medicare Advantage plan announcements and positive analyst coverage reinforce growth prospects.

ELV presents a compelling investment case with 71% analyst buy ratings and $445.13 price target offering 4.7% upside. However, declining 2026 profit margins to 2.46% and regulatory uncertainty in healthcare sector pose risks. The stock's current valuation at 18.81 P/E appears reasonable given earnings momentum and market position.

QXO trades at $11.02, up 3.57% on the day but down significantly year-to-date amid weak residential demand and integration challenges from its TopBuild acquisition. The stock shows neutral technical signals with support near $10-$11 and resistance at $12. Fundamentally, revenue grew to $6.84B in 2025 but net losses deepened to $279.4M, with a negative profit margin of -5.17% in 2026. Analyst sentiment remains bullish with a $22.89 consensus target, though recent news highlights margin pressure and execution risks.

The outlook hinges on successful integration of acquisitions and EBITDA growth targets, but high execution risk, negative earnings, and sector headwinds pose substantial downside. With 100% buy ratings from analysts and institutional accumulation, patient investors may see upside if management delivers on its playbook, though volatility is expected near-term.